

# COVID-19 infection during pregnancy on perinatal and neonatal outcomes: a scoping review

Saidatul Fauziah<sup>1\*</sup>, Mubasysyir Hasanbasri<sup>2</sup>, Vicka Oktaria<sup>2</sup>

## Abstract

**Submitted :**

January 15th, 2023

**Accepted:**

February 25th, 2023

**Published:**

February 28th, 2023

<sup>1</sup>Master of Public Health, Department of Biostatistics, Epidemiology, and Population Health, Faculty of Medicine, Public Health and Nursing, Universitas Gadjah Mada, Yogyakarta, Indonesia

<sup>2</sup>Department of Biostatistics, Epidemiology, and Population Health, Faculty of Medicine, Public Health and Nursing, Universitas Gadjah Mada, Yogyakarta, Indonesia

**\*Correspondence:**  
saidatulfauziah2@gmail.com

**Purpose:** COVID-19 infection has rapidly spread and caused a global pandemic, as stated by the World Health Organization on March 10, 2020. The incidence of COVID-19 tends to increase worldwide, including Indonesia, occasionally. With 6,422,529 confirmed cases, including 158,014 as of September 25, 2022, Indonesia has surpassed India and Bangladesh to become the nation with the third-highest confirmed cases in Asia. Although there have been reports of several cases of vertical transmission, the transmission of COVID-19 from mother to fetus was initially considered uncertain. Case reports of newborns (within the first 12 hours) with COVID-19 infection prove the possibility of intrauterine or extrauterine mother-infant vertical transmission. This study aimed to determine the effect of COVID-19 infection during pregnancy on perinatal and neonatal outcomes. **Methods:** This study employed the scoping review method, searching articles across several databases, including PubMed, Scopus, and Google Scholar, and adhered to the guidelines of PRISMA-ScR. Search for articles using the main keywords "pregnant women" or "pregnant" and "coronavirus" (or COVID-19 or 2019NCOV or SARS-CoV-2) AND ("perinatal outcome" or "neonatal outcome" or "pregnancy outcome") published in 2019–2022. **Results:** The articles obtained were related to symptoms of COVID-19-positive pregnant women, perinatal and neonatal outcomes of COVID-19 pregnant women, and the identification of COVID-19 occurrence during pregnancy. **Conclusion:** A total of 22 articles reviewed found that pregnant women with COVID-19 symptoms experience adverse outcomes in perinatal and neonatal compared to those not infected with COVID-19. Pregnant women with COVID-19 infection show a higher risk of perinatal and neonatal outcomes such as premature, LBW, and NICU admission.

**Keywords:** COVID-19; perinatal and neonatal outcomes; pregnant women; vertical transmission

## INTRODUCTION

The body undergoes several physiological changes during pregnancy, i.e., changes in hematology, respiration, cardiology, hormones, and immunity. As a result, this can increase the risk of susceptibility to diseases and infections, including COVID-19 [1,2]. The

emergence of COVID-19 poses new challenges for healthcare systems and practitioners, especially in the handling of pregnant women [3].

In March 2020, COVID-19 cases reached 180,000 confirmed worldwide, with 7,000 of those cases resulting in the deaths of pregnant women and fetuses, another high-risk category during the COVID-19

outbreak [4]. More than 90% of pregnant women infected with COVID-19 and hospitalized have pneumonia and premature birth [5]. The incidence of COVID-19 infection tends to rise, and serious complications that can occur due to changes in estrogen and progesterone levels, as well as alterations in immune function, may lead to an increase in the number of COVID-19 cases. Hormonal changes that begin in the first trimester of pregnancy cause respiratory, cardiovascular, and immune changes, making pregnant women and fetuses more vulnerable to COVID-19 infection [6].

Pregnant women have a high risk of developing complications from respiratory viral infections [7]. Physiological or immunological changes during pregnancy may have a systemic effect that predisposes women to complications of respiratory infections that result in maternal and fetal mortality and morbidity [8]. Severe COVID-19 has caused maternal-fetal death, intrauterine fetal growth restriction, spontaneous abortion, and premature birth [9].

Case reports of newborns (first 12 hours) infected with COVID-19 prove the possibility of mother-infant vertical transmission through intrauterine or extrauterine. This is supported by studies that demonstrate the presence of the COVID-19 virus in the placenta, amniotic fluid, cord blood, and breast milk, as well as maternal viremia [10-14]. In addition, not many studies have reported the impact of COVID-19 on the fetus, such as fetal distress, stillbirth, premature birth, neonatal asphyxia, and vertical transmission. However, there is a risk of fatal inflammatory response syndrome or other conditions that endanger the fetus [15,16].

Data on the impact of the COVID-19 virus from the mother on the fetus is still limited. It has been reported that viral pneumonia in pregnant women is associated with an increased risk of preterm birth, Fatal Growth Restriction (FGR), and perinatal death [17]. Research conducted by [18,19] found that of the nine pregnant women with COVID-19, 6% in the third trimester were negative for COVID-19 in samples of amniotic fluid, umbilical cord blood, throat and anal swabs, sputum, venous blood, and urine. These observations revealed no proof of vertically transmitted intrauterine infection in COVID-19 infected late-pregnant women. Meanwhile, another study found evidence of vertical transmission through intrauterine transmission, transmission during labor, breast milk transmission, and postnatal contact [20,21]. Vertical transmission can cause perinatal miscarriage, FGR, premature birth, and even stillbirth [22].

Based on the aforementioned research reports, variations exist in the relationship between COVID-19 and pregnancy, as well as neonatal and perinatal

outcomes. Therefore, researchers are interested in conducting further studies to obtain more accurate and up-to-date results. Thus, more information and evidence about COVID-19 during pregnancy are needed to provide an overview of the consequences, management, and handling of neonatal and perinatal outcomes.

## METHODS

Secondary data, using the scoping review method, began with determining the research question or problem formulation. The search for scientific articles to answer the research questions was then conducted by analyzing and interpreting these articles. The articles in question meet the inclusion and exclusion criteria under the PRISMA-ScR 2020 guidelines [23]. Information was obtained by reviewing scientific articles from several databases, including PubMed, ScienceDirect, and Google Scholar. The title, abstract, and content of the scientific article were screened based on the inclusion and exclusion criteria that have been determined. The information obtained was reviewed regarding 1) symptoms of pregnant women who are positive for COVID-19, 2) perinatal and neonatal outcomes of COVID-19 pregnant women, and 3) identification of COVID-19 events during pregnancy.

### Eligibility criteria

The provisions of scientific articles used in conducting research and writing the scoping review method meet the inclusion and exclusion criteria determined as follows: First, the inclusion criteria include articles using original studies, i.e., case-control, cohort, and cross-sectional, in English and Indonesian, Articles published in 2019–2021 on the influence of coronavirus infection during pregnancy on perinatal and neonatal outcomes, The population consisting of pregnant women infected with COVID-19, Intervention during the pregnancy lab-confirmed or clinically diagnosed COVID-19 infections in all health services, and Outcome containing information related to the effects of COVID-19 on neonatal and perinatal outcomes; and published in an electronic database in full or free full-text and both exclusion criteria. The criteria include limiting articles to those using the literature review method, conducting systematic and editorial reviews, excluding articles in languages other than Indonesian and English, and excluding pregnant women who tested negative from the study.

### Data source

A search was conducted through the PubMed, Scopus, and Google Scholar databases to identify

studies published from December 2019 to September 30, 2022. Problem formulation: "What is the influence of coronavirus infection 2019 (COVID-19) during pregnancy on neonatal and perinatal externalities?". This study adopts the PICO (Population, Intervention, Comparison, Outcome) framework to systematically formulate the research question and ensure a focused approach to the investigation. The Population (P) in this study comprises pregnant women, representing a high-risk group for complications during pregnancy, particularly amidst the COVID-19 pandemic. The Intervention (I) refers to infection with COVID-19 during pregnancy, while the Comparison (C) group consists of pregnant women without COVID-19 infection. The primary Outcomes (O) assessed include perinatal and neonatal outcomes. Table 1 shows search strategies that include keyword combinations compatible with medical subject headings (MeSH) with Boolean combinations to expand or limit the literature search as follows:

**Table 1. Search keyword PICO**

Database	Keywords
Pubmed	(Pregnancy[MeSH] OR "pregnant women"[MeSH] OR Pregnancy OR pregnant OR Pregnant*) AND (Coronavirus[MeSH] OR COVID-19[MeSH] OR "severe acute respiratory syndrome coronavirus 2"[MeSH] OR Covid[All Fields] OR Covid19[All Fields] OR COVID-19[All Fields] OR "covid 19"[All Fields] OR "corona"[All Fields] OR "2019 nCoV"[All Fields] OR 2019nCoV[All Fields] OR "2019 novel coronavirus"[All Fields] OR "COVID 19"[All Fields] OR "SARS CoV-2"[All Fields] OR "new coronavirus"[All Fields] OR "novel coronavirus"[All Fields] OR (Wuhan AND coronavirus)[All Fields] OR "SARS-CoV"[All Fields]) AND ("Perinatal outcome**" OR "neonatal outcome**" OR "Pregnancy outcome**")
Science Direct	(pregnant women OR Pregnant*) AND (Coronavirus OR COVID-19 OR 2019nCoV OR SARS CoV-2) AND (Perinatal outcome OR neonatal outcome OR Pregnancy outcome)
Google Scholar	(Pregnant mother OR pregnant woman) AND (Coronavirus OR COVID-19 OR 2019nCoV OR SARS CoV-2) AND (Perinatal outcome OR neonatal outcome OR Pregnancy outcome )

### Data selection

Two reviewers evaluated and determined which title to use based on its categorization, i.e., relevant, irrelevant, and potentially relevant titles. Following that, the reviewer and the researcher both evaluated the pertinent research abstract. The article was then reviewed twice—once by the researcher and once by the reviewer—as a whole. All studies that have been identified from a database search were exported to the EndNote Reference Management Software (EndNote version X9.3.3). Next, Rayyan's systematic review software was used to manage the self-screening process, which occurred concurrently with title screening, abstract screening, and full-text screening of


the same articles. Full-text exclusion reasons were documented at the full-text screening stage.

### Data extraction

The data from the included article were extracted into an Excel sheet by one researcher, and reviewers checked its accuracy. The extracted data included the study's characteristics (country, year of publication, research design and methodology, study period, population and setting, number of participants, number of cases, number in the control group, and dropouts).

### Data analysis techniques

Articles were selected using filter features in each database to facilitate the search based on predetermined inclusion and exclusion criteria. Filters used in the database to select articles included the publication period (2019-2021), the article research design (e.g., observational studies), and articles written in either English or Indonesian. The search results obtained from all databases were exported and then imported into the Zotero application to check the publication. This publication check was conducted to remove duplicate articles with the same title found in two or more databases. This aims to be more efficient in the next stage of selection, specifically screening the title and abstract of the article. The abstracts of the articles with titles irrelevant to the research topic were reviewed. If the title and abstract of the article discuss the adverse fetal and newborn outcomes of pregnant women infected with COVID-19, the next stage was conducted to assess the content of the article. The articles analyzed for the scoping review meet the inclusion criteria (Figure 1).



**Figure 1. ScR prism flow chart**

## RESULTS

### Literature search

The article search process was conducted from 2019 to 2022, yielding 1,488 articles (Figure 2) from multiple databases, including PubMed, ScienceDirect, and Google Scholar. The results of literature searches conducted through three databases were then screened based on inclusion and exclusion criteria using the ScrPrism guide. Twenty-two articles have been analyzed and meet the inclusion criteria for synthesis.

### Article characteristics and maternal clinical data

The general characteristics of the literature were analyzed based on the country of origin of the study, country category, study, morbidity in pregnant women,

and maternal symptoms. Researchers reviewed 22 articles from the screening results, with various characteristics summarized in Table 2.

Based on the results of studies that have been obtained from 22 articles, it was found that the effect of COVID-19 virus infection in pregnant women on perinatal and neonatal outcomes has ten outcomes: asphyxia, low birth weight of less than 2500 grams, respiratory distress, fetal distress, NICU admission, Oligohydramnios, prematurity, APGAR score less than seven at 5 minutes, APGAR score 4-6 at 5 minutes, and sepsis of the ten outcomes consisting of three outcomes with the highest number of occurrence, i.e., prematurity, low birth weight of less than 2500 grams, and NICU admission.




Figure 2. Outcome review results in perinatal and neonatal

Table 2. Characteristics of articles reviewed

Author (year)	Country	Method	Population of mother	Population of baby	Outcome (baby)	OR
Daclin et al. (2022) [24]	France	Case-control	86 COVID-19-positive pregnant women 86 COVID-19-negative pregnant women	172 newborn babies	The rate of preterm births among pregnant women positive for COVID-19 was 3.5% (n=3/86), compared to 4.7% (n=4/86) in those who tested negative.	Not reported
Elenga et al. (2022) [25]	France	Case-control	133 pregnant women tested positive for COVID-19 504 pregnant women tested negative for COVID-19	637 neonates	Preterm births among pregnant women positive and negative for COVID-19 (11%, n=15/133 vs. 7%, n=34/504). NICU admissions among neonates born to pregnant women are positive and negative for COVID-19 (14%, n=14/133 vs. 15%, n=77/504). Intrauterine fetal death (IUFD) among pregnant women positive and negative for COVID-19 (1.5%, n=2/133 vs. 1.0%, n=5/504).	OR= 12.5 [1.7-90.5] OR=13.4 [3.0-60] OR= 25.9 [2.2-305]
Gurol-Urganci et al. (2021) [26]	United Kingdom	Kohort	3,527 pregnant women tested positive for COVID-19 338,553 pregnant women tested negative for COVID-19	342,080 neonates	Preterm births among pregnant women positive and negative for COVID-19 (12.1%, n=369/3,047 vs. 5.8%, n=18,572/322,494). Low birth weight (LBW) among neonates born to pregnant women positive and negative for COVID-19 (6.4%, n=191/3,009 vs. 5.5%, n=17,521/320,188). Fetal death among pregnant women positive and negative for COVID-19 (0.85%, n=30/3,527 vs. 0.34%, n=1,140/338,553)	OR= 2.17 [1.96e2.42] OR=0.99 [0.8e1.16] OR= 2.21 [1.58e3.11]
Farhadi et al. (2022) [27]	Iran	Cross-sectional	58 pregnant women tested positive for COVID-19	60 newborns (including 2 twin pregnancies)	Among the 60 neonates included in this study, 41.2% (n = 25) were born prematurely. A total of 33.3% (n = 20) of the neonates tested positive for COVID-19. Low birth weight (LBW) was observed in 5.0% (n = 3) of the cases. Additionally, 56.7% (n = 34) of the neonates required admission to the Neonatal Intensive Care Unit (NICU), indicating a high rate of complications requiring specialized care.	Not reported
Gale et al. (2021) [28]	United Kingdom	Prospektif (cohort)	66 pregnant women tested positive for COVID-19	66 neonates	Out of the 66 neonates analyzed, 24% (n = 16) were born prematurely. COVID-19 positivity was detected in 42% (n = 28) of the neonates, indicating a significant rate of vertical or perinatal transmission. Furthermore, 12%	Not reported

Author (year)	Country	Method	Population of mother	Population of baby	Outcome (baby)	OR
Alipour et al. (2021) [29]	Iran	Retrospektif (cohort)	53 pregnant women tested positive for COVID-19  135 pregnant women tested negative for COVID-19	188 neonates	(n = 8) of the neonates developed nosocomial infections.  Preterm births among pregnant women positive and negative for COVID-19 were 47.2% (n = 25/53) and 13.3% (n = 18/135), respectively.  NICU admissions among neonates born to COVID-19-positive and COVID-19-negative mothers were 34.0% (n=18/53) and 7.4% (n=10/135), respectively.  Fetal distress was observed in 37.7% (n=20/53) of neonates from COVID-19 positive mothers, compared to 5.2% (n=7/135) from COVID-19 negative mothers.	OR = 3.01, 95% CI 1.4–6.54
Salvatore et al. (2020) [30]	United States of America	Cohort	116 pregnant women tested positive for COVID-19	120 neonates (including 4 twin pregnancies)	Eighty-two neonates were repeatedly tested, and all results were negative; none of the neonates showed symptoms.	Not reported
Wijaya & Wiyati (2021) [31]	Semarang, Indonesia	Case Control	51 pregnant women tested positive for COVID-19	51 neonates	Among the 51 neonates evaluated, 45% (n = 23) were classified as having low birth weight (LBW). Stillbirths occurred in 15.6% of cases (n = 8). Regarding birth asphyxia, 78.5% (n = 40) experienced mild asphyxia, 13.7% (n = 7) had moderate asphyxia, and 7.8% (n = 2) suffered from severe asphyxia.	Not reported
Sharma et al. (2021) [32]	India	Ambispective (including retrospective and prospective)	41 pregnant women tested positive for COVID-19	44 neonates (including 3 twin pregnancies)	Among the 44 neonates, 15.9% (n = 7) were born preterm. Low birth weight (LBW) was identified in 25% (n = 11) of the cases. A total of 13.6% (n = 6) required admission to the Neonatal Intensive Care Unit (NICU). Birth asphyxia was observed in 11.4% (n = 5), and an APGAR score of less than 7 at 5 minutes was recorded in the same proportion of	Not reported

Author (year)	Country	Method	Population of mother	Population of baby	Outcome (baby)	OR
					neonates (11.4%, n = 5).	
Choudhary et al. (2022) [33]	India	Retrospective cohort	107 pregnant women tested positive for COVID-19	107 neonates	Among the 107 neonates included in the analysis, 20.22% (n = 18) were born preterm, while low birth weight (LBW) was observed in 26.44% (n = 23) of the cases. Intrauterine fetal demise (IUFD) occurred in 3.81% (n = 4) of the pregnancies. Additionally, 2.25% (n = 3) of the newborns tested positive for COVID-19.	Not reported
Babic et al. (2022) [34]	Saudi Arabia	Retrospective cohort	209 pregnant women tested positive for COVID-19	209 neonates	Of the 209 neonates included in the study, 8.2% (n = 17) required admission to the Neonatal Intensive Care Unit (NICU). Neonatal COVID-19 infection was confirmed in 4.7% (n = 10) of the cases.	Not reported
Vural et al. (2022) [35]	Turkey	Retrospective cohort	61 pregnant women tested positive for COVID-19	63 neonates (including 2 twin pregnancies)	Among the 63 neonates studied, 9.52% (n = 6) were born prematurely. Respiratory disorders were identified in 31.75% (n = 20) of the cases, highlighting a significant burden of respiratory complications in this population.	Not reported
Shree et al. (2022) [36]	India	Retrospective cohort	49 pregnant women tested positive for COVID-19	49 neonates	Among the 49 neonates, 4.1% (n = 2) were born prematurely before 34 weeks of gestation. Low birth weight (LBW) was observed in 20.4% (n = 10) of the newborns. An APGAR score between 4 and 6 at 5 minutes was recorded in 8.2% (n = 4) of the cases. Additionally, neonatal COVID-19 positivity was confirmed in 2.0% (n = 1) of the neonates.	Not reported
Cuñarro- López et al. (2021) [8]	Spain	Ambispective cohort	(846 pregnant women positive for Covid-19 in the first wave);  (449 pregnant women positive for Covid-19 in the second wave)	1295 neonates	The rate of prematurity was 12.4% (n=105/846) in the first wave compared to 8.7% (n=39/449) in the second wave.	Not reported
Norman et al. (2021) [37]	Sweden	Cohort	(2,323 pregnant women positive for Covid-19);  (85,836 pregnant women negative for Covid-19)	(2,323 infants born to mothers positive for SARS-CoV-2);  (85,836 infants born to mothers negative for SARS-CoV-2)	Premature with gestational age <32 weeks (10.5%, n=4/38 vs. 8.3%, n=56/675)  Positive SARS-CoV-2 test results in infants, based on age:  Early neonates (0–6 days) (0.7%, n=16/2,323)	OR= -1.6; 95%[CI] -14.1-10.9  OR= 0.7; 95%[CI] 0.4-1.0

Author (year)	Country	Method	Population of mother	Population of baby	Outcome (baby)	OR
					vs. <0.1%, n=2/85,836)	
					Late neonates (7–28 days) (0.2%, n=5/2,323 vs. 0.1%, n=47/85836)	OR= 0,2; 95%[CI] -0.0-0.4
					Postneonatal (<28 days) (<0.1%, n=1/2,323 vs. 0.3%, n=230/85,836)	OR= - 0,2; 95%[CI] -0.4 - -0.1
Hcini et al. (2021) [38]	France	Cohort	137 mothers who gave birth while infected with Covid-19;  370 mothers who gave birth without Covid-19 infection	137 neonates born to mothers positive for Covid-19;  370 neonates born to mothers negative for Covid-19, including 5 twin pregnancies	NICU admission among neonates born to Covid-19 positive and negative mothers (2.3%, n=3/127 vs. 3.2%, n=12/364)  Respiratory disorders among neonates born to Covid-19 positive and negative mothers (3.1%, n=4/127 vs. 4.3%, n=16/364)  Neonates positive for Covid-19 born to Covid-19 positive mothers (33%, n=4/29)	Not reported
Gupta et al. (2021) [39]	India	Retrospective cohort	108 pregnant women tested positive for COVID-19  3057 pregnant women tested negative for COVID-19	3,165 neonates	5-minute APGAR score <7 among neonates born to Covid-19 positive and negative mothers (6.48%, n=7/108 vs. 2.7%, n=83/3,057)*  Fetal distress among Covid-19 positive and negative mothers (22.2%, n=24/108 vs. 10.9%, n=334/3,057)	Not reported
Antoun et al. (2020) [40]	England	Retrospective cohort	19 pregnant women tested positive for COVID-19	19 newborns tested negative for Covid-19	Among the 19 neonates evaluated, 36.8% (n = 7) were born preterm. Respiratory distress syndrome was diagnosed in 15.8% (n = 3) of the cases	Not reported
Al Hashmi et al. (2022) [41]	Oman	Case-control	87 pregnant women tested positive for COVID-19  87 pregnant women tested negative for COVID-19	87 neonates positive for Covid-19;  87 neonates negative for Covid-19	Low APGAR score among neonates born to Covid-19 positive and negative mothers (1.1%, n=1/87 vs. 0%)  NICU admission among neonates born to Covid-19 positive and negative mothers (16.1%, n=14/87 vs. 0%)	Not reported
Dileep et al. (2022) [42]	United Arab Emirates	Retrospective cohort	200 pregnant women tested positive for COVID-19	200 neonates	Among the 200 neonates included in the study, 35.0% (n = 70) were born preterm. Admission to the Neonatal Intensive Care Unit (NICU) was required for 33.0% (n = 66) of the cases. Low birth weight (LBW) was observed in 30.5% (n = 61) of the neonates. Additionally, neonatal infections were documented in 17.0% (n = 34) of the newborns.	Not reported

Author (year)	Country	Method	Population of mother	Population of baby	Outcome (baby)	OR
Akbarian-Rad et al. (2021) [43]	Iran	Retrospective	8 pregnant women tested positive for COVID-19	8 neonates	Among the 8 neonates assessed, low birth weight (LBW) was observed in 1.25% (n = 1) of cases.	Not reported
Gomez et al. (2022) [44]	Brazil	Prospective study	<p>A total of 734 pregnant women were divided into the following groups:</p> <p>C0 = 357 (Covid-19 negative results)</p> <p>C1 = 127 (Covid-19 positive results, asymptomatic)</p> <p>C2 = 174 (Covid-19 positive with mild symptoms)</p> <p>C3 = 37 (Covid-19 positive with moderate symptoms)</p> <p>C4 = 39 (Covid-19 positive with severe symptoms)</p>	734 neonates	<p>NICU Admission:</p> <p>C1 (10.4%, n=13/125)</p> <p>C2 (22%, n=39/177)</p> <p>C3 (18.4%, n=38/207)</p> <p>C4 (63.9%, n=23/36)</p> <p>Oligohydramnios:</p> <p>C1 (3.3%, n=4/133)</p> <p>C2 (8.3%, n=15/181)</p> <p>C3 (13.2%, n=5/38)</p> <p>C4 (12.2%, n=5/41)</p> <p>Fetal distress:</p> <p>C1 (11%, n=14/127)</p> <p>C2 (12.8%, n=23/179)</p> <p>C3 (10.5%, n=4/38)</p> <p>C4 (30.7%, n=12/39)</p>	<p>NICU Admission:</p> <p>C1 → OR = 1.24; 95%(CI): 0.35–4.39</p> <p>C2 → OR = 3.68; 95%(CI): 1.43–9.48</p> <p>C3 → OR = 5.21; 95%(CI): 1.15–23.67</p> <p>C4 → OR = 19.36; 95%(CI): 5.86–63.99</p> <p>Oligohydramnios:</p> <p>C1 → OR = 1.37; 95%(CI): 0.40–4.63</p> <p>C2 → OR = 3.77; 95%(CI): 1.15–23.67</p> <p>C3 → OR = 19.36; 95%(CI): 5.86–63.99</p> <p>Fetal distress:</p> <p>C1 → OR = 1.15; 95%(CI): 0.59–2.21</p> <p>C2 → OR = 1.31; 95%(CI): 0.74–2.31</p> <p>C3 → OR = 1.04; 95%(CI): 0.35–3.12</p> <p>C4 → OR = 4.01; 95%(CI): 1.84–8.75</p>

## DISCUSSION

The results showed that prematurity in perinatal and neonatal infections with COVID-19 was caused by pregnant women infected with COVID-19 during pregnancy, including acute COVID-19 [25,27]. On the other hand, the environment can trigger a significant increase in prematurity related to the ethnicity or tribe of pregnant women infected with COVID-19 and the occurrence of nosocomial transmission [28,29]. In addition to the environmental factors identified in the research of [33,42], comorbidities such as pneumonia and liver dysfunction may be significant contributing factors to premature birth.

Based on the results of studies, it was found that NICU admission was caused by prematurity and infants infected with COVID-19 from their mothers. In addition, according to [45,34], strict breathing and observation cause neonatals infected with COVID-19 to need to receive exceptional care in the NICU room. Another study reported that NICU admission can also be caused when the mother giving birth confirms COVID-19, so it is necessary to do further examination of the neonate [32]. Findings from [42] discuss multigravid pregnant women and the incidence of low birth weight babies less than 2500 grams. Moreover, pregnant women with COVID-19 have a higher risk of giving birth to babies with LBW.

In addition to the occurrence of premature outcomes, NICU admission, and low birth weight <2500 grams, mortality is also an occurrence in perinatal and neonatal. This statement is supported by previous research showing that prenatal and neonatal mortality are significantly common in pregnant women infected with COVID-19, based on laboratory results at the time of birth (30 of 3527 or 8.5 per 1000) [26]. Regarding the increased risk of fetal death and adverse pregnancy outcomes in perinatal and neonatal settings from COVID-19-infected pregnant women, [35] states that COVID-19 infection is related to the risk of morbidity and mortality of pregnant women and babies, especially if they already have symptoms and comorbidities, thereby aggravating the baby's condition. Overall, COVID-19 pregnant women have a lower rate of spontaneous deliveries but a higher rate of sectio caesarea deliveries, which is indicative of a higher rate of pregnancy complications in pregnant women with COVID-19.

## CONCLUSION

A total of 22 articles reviewed found that pregnant women with COVID-19 symptoms experience adverse outcomes in perinatal and neonatal compared to those not infected with COVID-19. Pregnant women with COVID-19 infection show a higher risk of perinatal and neonatal outcomes, such as premature, LBW, and NICU admission.

Factors contributing to perinatal and neonatal outcomes of pregnant women with COVID-19 include: COVID-19 infection, ethnicity/race, nosocomial transmission, co-morbidities, and multigravida pregnant women. The most common clinical symptoms of COVID-19 in pregnancy are cough, fever, diarrhea, gastrointestinal symptoms, stuffy nose, malaise, rhinitis, and rhinorrhea. In addition, COVID-19 related to co-morbidities worsens the condition of the mother.

## REFERENCES

1. Cunningham FG, Leveno KJ, Bloom SL, Spong CY, Dashe JS, Hoffman BL, et al. *Williams obstetrics*. New York: McGraw-Hill; 2018. Available from: [\[Website\]](#)
2. National Institutes of Health. About pregnancy. 2017. Available from: [\[Website\]](#)
3. Mertz D, Geraci J, Winkup J, Gessner BD, Ortiz JR, Loeb M. Pregnancy as a risk factor for severe outcomes from influenza virus infection: A systematic review and meta-analysis of observational studies. *Vaccine*. 2017;35(4):521-528.
4. World Health Organization. What is a pandemic, frequently asked questions. 2020. Available from: [\[Website\]](#)
5. Di Mascio D, Khalil A, Saccone G, Rizzo G, Buca D, Liberati M, et al. Outcome of coronavirus spectrum infections (SARS, MERS, COVID-19) during pregnancy: a systematic review and meta-analysis. *American Journal of Obstetrics and Gynecology MFM*. 2020;2(2):100107.
6. Schwartz DA, Dhaliwal A. Coronavirus diseases in pregnant women, the placenta, fetus, and neonate. *Advances in Experimental Medicine and Biology*. 2021;1318:223-241.
7. Almuslim H, AlDossary S. Models of incorporating telehealth into obstetric care during the COVID-19 pandemic, its benefits and barriers: a scoping review. *Telemedicine Journal and E-Health*. 2022; 28(1):24-38.

8. Cuñarro-López Y, Pintado-Recarte P, Hernández-Martín C, Paya-Martínez P, López-Pérez R, Cueto-Hernández I, et al. Comparing infection profiles of expectant mothers with COVID-19 and impacts on maternal and perinatal outcomes between the first two waves of the pandemic. *Journal of Personalized Medicine*. 2021;11(7):599.
9. Godoi APN, Bernardes GCS, Nogueira LS, Alpoim PN, de Barros Pinheiro M. Clinical features and maternal-fetal results of pregnant women in COVID-19 times. *Revista Brasileira de Ginecologia e Obstetrícia / RBGO Gynecology and Obstetrics*. 2021; 43(5):384–394.
10. Dong L, Tian J, He S, Zhu C, Wang J, Liu C, et al. Possible vertical transmission of SARS-CoV-2 from an infected mother to her newborn. *JAMA*. 2020; 323(18):1846-1848.
11. Lamouroux A, Attie-Bitach T, Martinovic J, Leruez-Ville M, Ville Y. Evidence for and against vertical transmission for severe acute respiratory syndrome coronavirus 2. *American Journal of Obstetrics and Gynecology*. 2020;223(1):91.e1-91.e4.
12. Vivanti AJ, Vauloup-Fellous C, Prevot S, Zupan V, Suffee C, do Cao J, et al. Transplacental transmission of SARS-CoV-2 infection. *Nature Communications*. 2020;11(1):3572.
13. Walker K, O'Donoghue K, Grace N, Dorling J, Comeau J, Li W, Thornton J. Maternal transmission of SARS-CoV-2 to the neonate, and possible routes for such transmission: a systematic review and critical analysis. *BJOG: An International Journal of Obstetrics & Gynaecology*. 2020;127(11):1324–1336.
14. Wang C, Zhou Y-H, Yang H-X, Poon LC. Intrauterine vertical transmission of SARS-CoV-2: what we know so far. *Ultrasound in Obstetrics & Gynecology*. 2020;55(6):724–725.
15. Chen L, Li Q, Zheng D, Jiang H, Wei Y, Zou L, et al. Clinical characteristics of pregnant women with COVID-19 in Wuhan, China. *The New England Journal of Medicine*. 2020;382(25):e100.
16. Zhao X, Jiang Y, Zhao Y, Xi H, Liu C, Qu F, et al. Analysis of the susceptibility to COVID-19 in pregnancy and recommendations on potential drug screening. *European Journal of Clinical Microbiology & Infectious Diseases*. 2020;39(7):1209–1220.
17. Chamseddine RS, Wahbeh F, Chervenak F, Salomon LJ, Ahmed B, Rafii A. Pregnancy and neonatal outcomes in SARS-CoV-2 infection: a systematic review. *Journal of Pregnancy*. 2020;4592450.
18. Chen H, Guo J, Wang C, Luo F, Yu X, Zhang, et al. Clinical characteristics and intrauterine vertical transmission potential of COVID-19 infection in nine pregnant women: a retrospective review of medical records. *The Lancet*. 2020;395(10226):809–815.
19. Peng Z, Wang J, Mo Y, Duan W, Xiang G, Yi M, et al. Unlikely SARS-CoV-2 vertical transmission from mother to child: A case report. *Journal of Infection and Public Health*. 2020;13(5):818–820.
20. Arora N, Sadovsky Y, Dermody TS, Coyne CB. Microbial vertical transmission during human pregnancy. *Cell Host & Microbe*. 2017;21(5):561–567.
21. Silasi M, Cardenas I, Kwon J-Y, Racicot K, Aldo P, Mor G. Viral infections during pregnancy. *American Journal of Reproductive Immunology*. 2015;73(3): 199–213.
22. Yang Z, Liu Y. Vertical transmission of severe acute respiratory syndrome coronavirus 2: a systematic review. *American Journal of Perinatology*. 2020;37 (10):1055–1060.
23. Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. *BMJ*. 2021;372:n71.
24. Daclin C, Carbonnel M, Rossignol M, Abbou H, Trabelsi H, Cimmino A, et al. Impact of COVID-19 infection in pregnancy and neonates: A case control study. *Journal of Gynecology Obstetrics and Human Reproduction*. 2022;51(5):102366.
25. Elenga N, Wandji MJ, Siban J, Nacher M, Demar M. Neonatal outcomes related to maternal SARS-CoV-2 infection in French Guiana: A case-control study. *Journal of Infection and Public Health*. 2022;15(7): 746–751.
26. Gurol-Urganci I, Jardine JE, Carroll F, Draycott T, Dunn G, Fremeaux A, et al. Maternal and perinatal outcomes of pregnant women with SARS-CoV-2 infection at the time of birth in England: national cohort study. *American Journal of Obstetrics and Gynecology*. 2021;225(5):522.e1-522.e11.
27. Farhadi R, Ghaffari V, Mehrpisheh S, Moosazadeh M, Haghshenas M, Ebadi A. Characteristics and outcome of infants born to mothers with SARS-CoV-2 infection during the first three waves of COVID-19 pandemic in northern Iran: A prospective cross-sectional study. *Annals of Medicine & Surgery*. 2022;78:103839.
28. Gale C, Quigley MA, Placzek A, Knight M, Ladhani S, Draper ES, et al. Characteristics and outcomes of neonatal SARS-CoV-2 infection in the UK: a prospective national cohort study using active surveillance. *The Lancet Child & Adolescent Health*. 2021;5(2):113–121.
29. Alipour Z, Samadi P, Eskandari N, Ghaedrahamati M, Vahedian M, Khalajinia Z, et al. Relationship between coronavirus disease 2019 in pregnancy and maternal and fetal outcomes: Retrospective analytical cohort study. *Midwifery*. 2021;102: 103128.

30. Salvatore CM, Han JY, Acker KP, Tiwari P, Jin J, Brandler M, et al. Neonatal management and outcomes during the COVID-19 pandemic: an observation cohort study. *The Lancet Child and Adolescent Health*. 2020;4(10):721–727.

31. Wijaya DM, Wiyati PS. Acute coagulopathy in preterm maternal with COVID-19: Lesson learned from DR. Kariadi Hospital Semarang. 2021;47(4): 124–134.

32. Sharma R, Seth S, Sharma R, Yadav S, Mishra P, Mukhopadhyay S. Perinatal outcome and possible vertical transmission of coronavirus disease 2019: experience from North India. *Clinical and Experimental Pediatrics*. 2021;64(5):239–246.

33. Choudhary A, Singh V, Bharadwaj M. Maternal and neonatal outcomes in pregnant women with SARS-CoV-2 infection complicated by hepatic dysfunction. *Cureus*. 2022;14(5):e25347.

34. Babic I, Alsomali F, Aljuhani S, Baeissa S, Alhabib I, AlAhmari E, et al. COVID-19 pandemic and its impact on perinatal outcomes between symptomatic and asymptomatic women. *Obstetrics and Gynecology International*. 2022;1756266.

35. Vural T, Bayraktar B, Yildirim Karaca S, Odabas O, Yilmaz N, Samlioglu P, et al. Comparison of maternal, perinatal, and neonatal outcomes of asymptomatic and symptomatic pregnant women with coronavirus disease-2019. *Medeniyet Medical Journal*. 2022;37:44–53.

36. Shree P, Mittal N, Vishwakarma S, Verma V, Pandey V, Thadani E. Maternal and perinatal outcomes of COVID-19-positive pregnant women. *Cureus*. 2022; 14(6):e26411.

37. Norman M, Navér L, Söderling J, Ahlberg M, Hervius Askling H, Aronsson B, et al. Association of maternal SARS-CoV-2 infection in pregnancy with neonatal outcomes. *JAMA*. 2021;325(20):2076–2086.

38. Hcini N, Maamri F, Picone O, Carod JF, Lambert V, Mathieu M, et al. Maternal, fetal and neonatal outcomes of large series of SARS-CoV-2 positive pregnancies in peripartum period: A single-center prospective comparative study. *European Journal of Obstetrics and Gynecology and Reproductive Biology*. 2021;257:11–18.

39. Gupta P, Kumar S, Sharma SS. SARS-CoV-2 prevalence and maternal-perinatal outcomes among pregnant women admitted for delivery: Experience from COVID-19-dedicated maternity hospital in Jammu, Jammu and Kashmir (India). *Journal of Medical Virology*. 2021;93(9):5505–5514.

40. Antoun L, Taweele NE, Ahmed I, Patni S, Honest H. Maternal COVID-19 infection, clinical characteristics, pregnancy, and neonatal outcome: A prospective cohort study. *European Journal of Obstetrics & Gynecology and Reproductive Biology*. 2020;252: 559–562.

41. Al Hashmi I, Khalaf A, Seshan V, Alsabti H, Al Omari, O, Yehia D, et al. Maternal and neonatal outcomes of healthy pregnant women with COVID-19 versus high-risk pregnant women: a multi-center case-control comparison study. *Clinical Nursing Research*. 2022;31(4):702–712.

42. Dileep A, ZainAlAbdin S, AbuRuz S. Investigating the association between severity of COVID-19 infection during pregnancy and neonatal outcomes. *Scientific Reports*. 2022;12(3024).

43. Akbarian-Rad Z, Mojaveri MH, Bouzari Z, Sadeghi F, Yahyapour Y, Rad MN, et al. Neonatal outcomes in pregnant women infected with COVID-19 in Babol, North of Iran: a retrospective study with short-term follow-up. *Infectious Diseases in Obstetrics and Gynecology*. 2021;9952701.

44. Gomez UT, Francisco RPV, Baptista FS, Gibelli MABC, Ibidi SM, de Carvalho WB, et al. Impact of SARS-CoV-2 on pregnancy and neonatal outcomes: An open prospective study of pregnant women in Brazil. *Clinics*. 2022;77:100073.

45. Zhu H, Wang L, Fang C, Peng S, Zhang L, Chang G, et al. Clinical analysis of 10 neonates born to mothers with 2019-nCoV pneumonia. *Translational Pediatrics*. 2020;9(1):51–60.